Quantcast

Latest Mantle cell lymphoma Stories

2014-03-25 23:31:01

Researchers say a drug approved for the treatment of relapsed T-cell Non-Hodgkin’s Lymphoma may help people with indolent B-cell varieties, too Raleigh, North

2014-03-22 23:02:28

Researchers say a drug approved for the treatment of relapsed T-cell Non-Hodgkin’s Lymphoma may help people with indolent B-cell varieties, too. Raleigh, NC

2014-03-12 23:24:38

Researchers say a combination of bendamustine and rituximab may be just as effective and less toxic than standard chemotherapy for indolent lymphomas. Raleigh,

2014-03-11 08:32:04

NEWTOWN, Pa., March 11, 2014 /PRNewswire/ -- BioClinica®, Inc., a leading provider of specialized outsourced clinical

2014-03-10 12:24:08

WASHINGTON, March 10, 2014 /PRNewswire-USNewswire/ -- A pill that suppresses a key regulator of cancer growth may provide hope to relapsed leukemia and lymphoma patients running out of treatment

2014-02-22 23:01:25

Careful screening is recommended to protect Non-Hodgkin’s Lymphoma patients against this dangerous side effect of rituximab. Raleigh, NC (PRWEB) February 22,

2014-02-20 16:25:31

Company launches its first product, IMBRUVICA(TM), and records net product revenue of $13.6 million SUNNYVALE, Calif., Feb. 20, 2014 /PRNewswire/ -- Pharmacyclics, Inc.

2014-02-13 12:27:27

FLINT, Mich., Feb. 13, 2014 /PRNewswire-iReach/ -- Diplomat, the country's largest independent specialty pharmacy, announced today that IMBRUVICA(TM) (ibrutinib) was approved by the U.S.

2014-02-12 16:26:29

CLL is second indication approved by FDA for ibrutinib; previously approved for mantle cell lymphoma patients WHITE PLAINS, N.Y., Feb. 12, 2014 /PRNewswire/ -- Today's U.S.

2014-02-12 16:25:59

HORSHAM, Pa., Feb. 12, 2014 /PRNewswire/ -- Janssen Biotech, Inc. ["Janssen"] today announced the U.S.